Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.

BMC research notes - 25 Apr 2012

Feigelson Heather Spencer, Goddard Katrina A B, Johnson Monique A, Funk Kellyan C, Rahm Alanna Kulchak, Kauffman Tia L, Chitale Dhananjay A, Le Marchand Loic, Richards C Sue

Abstract excerpt

BACKGROUND: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, techniques for tumor enrichment, DNA preparation, assay design and sensitivity. We evaluated comparability and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Clinical Laboratory Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guidelines as Topic

Share to Observer Variation

Share to Paraffin Embedding

Share to Quality Control

Share to ras Proteins

Share to Tissue Fixation

Source

Open in PubMed Open full text

Identifiers

PMID: 22534075
DOI: 10.1186/1756-0500-5-196
PMCID: PMC3441241

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.PMID 22534075Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.Semantic proximity Read ↗

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.Semantic proximity Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?Semantic proximity Read ↗

Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.